• Alligator Bioscience’s third-quarter loss widened 36% year over year to SEK 16.67 million.
• Net sales fell 49% year over year to SEK 237,000.
• A rights issue raised SEK 58.8 million before issue costs; SEK 19 million in bridge loans were repaid.
• Financing remains unsecured for the coming 12 months, raising material uncertainty over the ability to continue as a going concern.
• Independent mitazalimab development was discontinued to refocus operations on the financial interest in HLX22, currently in global Phase 3 development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alligator Bioscience AB published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.